NLRP3 and metabolic dysfunction-associated steatohepatitis: This interpretation is consistent with previous observations showing that Nlrp3 gene deletion [18] or NLRP3 blockade [17] attenuates hepatic inflammation and fibrosis in animal models of NASH, and also with the evidence that these strategies are effective in attenuating other experimentally induced liver diseases [14].